Investigation on the Role of Gut-liver Axis for Non-alcoholic Steatohepatitis Through Bariatric Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-16

Study Completion Date

2024-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Non-alcoholic steatohepatitis (NASH) is an aggressive form of NAFLD with remarkable inflammatory features which may cause advanced fibrosis and liver cancer. So far there is no FDA-approved drug for treating NASH. A 10% weight loss by life style modification is a standard recommendation to treat NASH which achieves only 10-20% success rate in clinical practice. Thus, the development of therapeutics to prevent and treat NASH is certainly an unmet need. For now, the mechanism of how simple steatosis progresses to NASH remains unclear and accumulating evidences suggest the role of gut microbiota may be essential. Studies have also noted the bariatric surgery effectively improve diabetes and NASH with significant alterations in the composition and function of gut microbiome. In this study, the investigators aim to investigate the role of gut microbiota in the pathophysiology of NASH by comparing NAFLD severity, gut microbiome, metabolomics, immune profiles among patients before and after the bariatric surgery. With these efforts, the investigators wish to decipher the mechanism of how bariatric surgery may improve NASH through changing the gut microbiota and find out microbe-associated molecular signatures between NASH and NAFLD through this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Bariatric Surgery for NAFLD/NASH

NCT04366999

Bariatric Surgery Candidate NAFLD NASH With Fibrosis

RECRUITING

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

NCT00280527

Obesity

COMPLETED

The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease

NCT01619215

Obesity, Morbid Non-Alcoholic Fatty Liver Disease

UNKNOWN

The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease

NCT04127370

NAFLD Bariatric Surgery Candidate

UNKNOWN NA

the Related Factors of Bariatric Surgery on Liver Function

NCT03689790

Liver Function Bariatric Surgery

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators anticipate to recruit 140 morbidly obese patients who will receive bariatric surgery including 100 patients receiving sleeve gastrectomy (SG) and 40 receiving gastric bypass surgery (GB). Liver biopsy will be performed during the operation to confirm the histological scores of NAFLD severity. The investigators expect to have 50% NASH and 50% NAFL patients from these morbidly obese patients based on previous domestic data. (i.e. 50 patients receiving SG to have NASH and 50 patients receiving SG to have NAFL; 20 patients receiving GB to have NASH and 20 patients receiving GB to have NAFL.) In this study, the investigators have two study objectives which are as follows.

1. The first objective is to discover potential mechanisms among gut-liver axis for preventing or promoting NAFL to NASH by comparing (1) fecal microbiome composition and metabolomics, (2) peripheral blood biochemistry, metabolomics, immune cell phenotypes, and cytokines (3) portal vein biochemistry, metabolomics, immune cell phenotypes, and cytokines (4) Liver metabolomics and RNA-seq (5) gut permeability test (lactulose/mannitol challenge) (6) host genetic susceptibility for NAFLD (PNPLA3 and TM6SF2) between the tissue-proved NASH and NAFL patients in this study with a cross-sectional comparison.
2. The second objective is to longitudinally investigate the potential mechanisms of bariatric surgery for improving NASH via a gut-microbiota dependent pathway. Clinical and experimental data before (baseline) and after (1st, 3rd, 6th months) bariatric surgery will be collected which include (1) non-invasive evaluation of NAFLD severity (Fibroscan, MRI-PDFF (proton density fat fraction) and MRE), (2) blood biochemistry, metabolomics, immune cell phenotypes, and cytokines (3) fecal microbiome and metabolomics (4) gut permeability test (5) liver biopsy histology (if available)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Steatohepatitis Bariatric Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese patients tissue proved NASH

age \>20，morbid obesity who will receive bariatric surgery, tissue proved NASH

No interventions assigned to this group

Obese patients tissue proved NAFL

age \>20，morbid obesity who will receive bariatric surgery, tissue proved NAFL

No interventions assigned to this group

NASH (before bariatric surgery)

age \>20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected before bariatric surgery.

Bariatric surgery

Intervention Type PROCEDURE

Bariatric surgery

NASH (after bariatric surgery)

age \>20，morbid obesity receiving bariatric surgery and was proved NASH histologically. Data collected after bariatric surgery.

Bariatric surgery

Intervention Type PROCEDURE

Bariatric surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bariatric surgery

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Liver biopsy Portal vein sampling

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Age \>20，morbidly obese patients who will receive bariatric surgery.

Exclusion Criteria

* Average daily alcohol intake \>20 grams,
* Hepatitis B carriers, Hepatitis C carriers,
* people with liver disease caused by other causes
* liver cirrhosis,
* diseases related to abnormal blood coagulation,
* inflammatory bowel disease,
* routine use of steroids or immunity Inhibitors and other immunomodulatory drugs
* ursodeoxycholic and other drugs that affect bile acid metabolism
* those who have used antibiotics or probiotics within one month

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes